Associated Papers
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes.
El-Boraie A et al.
Clinical and Translational Science, 2022
Deciphering Structural Alterations Associated with Activity Reductions of Genetic Polymorphisms in Cytochrome P450 2A6 Using Molecular Dynamics Simulations.
Kato K et al.
International Journal of Molecular Sciences, 2021
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Variation in CYP2A6 Activity and Personalized Medicine.
Tanner JA et al.
Journal of Personalized Medicine, 2017
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities.
Hosono H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2017
Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.
López-Flores LA et al.
Excli Journal, 2017
CYP2A6 genetic polymorphism is associated with decreased susceptibility to squamous cell lung cancer in Japanese smokers.
Hosono H et al.
Drug Metabolism and Pharmacokinetics, 2015
Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.
Yamamiya I et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2014
Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects.
Wang TH et al.
The Aaps Journal, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Zanger UM et al.
Pharmacology & Therapeutics, 2013
Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans.
Djordjevic N et al.
Drug Metabolism and Pharmacokinetics, 2013
Cytochrome p450 metabolism of betel quid-derived compounds: implications for the development of prevention strategies for oral and pharyngeal cancers.
Lin CY et al.
Thescientificworldjournal, 2013
Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35).
Han S et al.
Biological & Pharmaceutical Bulletin, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.
Tanii H et al.
European Journal of Clinical Pharmacology, 2011
A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.
Al Koudsi N et al.
The Pharmacogenomics Journal, 2009
Smoking behavior and related cancers: the role of CYP2A6 polymorphisms.
Nakajima M
Current Opinion in Molecular Therapeutics, 2007
Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research.
Wall TL et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco, 2007
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M et al.
Clinical Pharmacology and Therapeutics, 2006
Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
Kimura M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Three haplotypes associated with CYP2A6 phenotypes in Caucasians.
Haberl M et al.
Pharmacogenetics and Genomics, 2005
Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
Nakajima M et al.
Drug Metabolism and Pharmacokinetics, 2005
Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.
Mwenifumbo JC et al.
Pharmacogenetics and Genomics, 2005
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
Fujieda M et al.
Carcinogenesis, 2004
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T et al.
Clinical Pharmacology and Therapeutics, 2004
Novel human CYP2A6 alleles confound gene deletion analysis.
Nakajima M et al.
Febs Letters, 2004
Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.
Yoshida R et al.
Clinical Pharmacology and Therapeutics, 2003
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
Tricker AR
Toxicology, 2003
Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.
Yoshida R et al.
British Journal of Clinical Pharmacology, 2002
Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.
Nakajima M et al.
Drug Metabolism Reviews, 2002
Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.
Tyndale RF et al.
Therapeutic Drug Monitoring, 2002
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles.
Xu C et al.
Biochemical and Biophysical Research Communications, 2002
A novel single nucleotide polymorphism altering stability and activity of CYP2a6.
Ariyoshi N et al.
Biochemical and Biophysical Research Communications, 2001